Leslie Trigg Sells 3,437 Shares of Outset Medical (NASDAQ:OM) Stock

Posted by Stanley Muller on Aug 18th, 2026

Outset Medical, Inc. (NASDAQ:OM – Get Free Report) CEO Leslie Trigg sold 3,437 shares of the firm’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $4.39, for a total transaction of $15,088.43. Following the sale, the chief executive officer directly owned 194,597 shares of the company’s stock, valued at $854,280.83. The trade was a 1.74% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Outset Medical Stock Down 7.3%

Shares of NASDAQ:OM traded down $0.33 during midday trading on Tuesday, reaching $4.18. The company had a trading volume of 143,860 shares, compared to its average volume of 129,697. The company has a debt-to-equity ratio of 1.03, a current ratio of 5.19 and a quick ratio of 4.11. The stock’s fifty day moving average price is $4.57 and its 200-day moving average price is $4.23. The stock has a market capitalization of $78.58 million, a P/E ratio of -1.02 and a beta of 1.96. Outset Medical, Inc. has a one year low of $3.00 and a one year high of $16.16.

Outset Medical (NASDAQ:OM – Get Free Report) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.08). The company had revenue of $31.64 million for the quarter, compared to the consensus estimate of $28.97 million. Outset Medical had a negative net margin of 63.06% and a negative return on equity of 61.67%. Equities research analysts expect that Outset Medical, Inc. will post -3.8 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

OM has been the subject of a number of research reports. TD Cowen reiterated a “buy” rating on shares of Outset Medical in a research note on Friday, May 8th. Weiss Ratings raised Outset Medical from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, August 7th. Finally, Wall Street Zen upgraded Outset Medical from a “sell” rating to a “hold” rating in a research report on Saturday. Three analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Outset Medical has a consensus rating of “Hold” and a consensus price target of $10.00.

View Our Latest Stock Report on OM

Institutional Investors Weigh In On Outset Medical

A number of institutional investors have recently modified their holdings of OM. Legal & General Group Plc bought a new position in Outset Medical in the second quarter worth about $34,000. BNP Paribas Financial Markets grew its holdings in shares of Outset Medical by 7,013.8% during the second quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the last quarter. Bank of New York Mellon Corp grew its holdings in shares of Outset Medical by 4.1% during the first quarter. Bank of New York Mellon Corp now owns 62,360 shares of the company’s stock valued at $239,000 after purchasing an additional 2,435 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Outset Medical by 0.8% during the 4th quarter. Geode Capital Management LLC now owns 400,363 shares of the company’s stock worth $1,486,000 after purchasing an additional 3,104 shares during the period. Finally, Barclays PLC raised its position in shares of Outset Medical by 9.8% during the 4th quarter. Barclays PLC now owns 37,682 shares of the company’s stock worth $140,000 after purchasing an additional 3,356 shares during the period.

About Outset Medical

(Get Free Report)

Outset Medical is a medical technology company specializing in innovations for renal care. The company’s flagship offering, the Tablo Hemodialysis System, is designed to streamline and simplify dialysis treatment across acute and outpatient settings. By integrating water purification, dialysate production, and treatment monitoring into a single device, Tablo aims to reduce the complexity and logistical burden traditionally associated with hemodialysis therapy.

Tablo’s modular design allows for rapid setup and flexible deployment in hospitals, clinics, long‐term care facilities and emergency response scenarios.